Parallel Biosystems Analysis: $4M Raised
What is Parallel Biosystems?
Parallel Biosystems develops immunotherapies using immune organoids and AI to create effective drugs, aiming to revolutionize drug discovery without traditional clinical trials.
Employees
9
Founded
2021
Company Stage
Seed
YC Batch
S21
Product Features & Capabilities
- Trial-in-a-Dish, Disease Modeling, Target Discovery, Predict drug safety in diverse populations, Create realistic disease models, Identify novel drug targets
How much Parallel Biosystems raised
Seed - $4.3 million
December 20, 2022Lead Investor: Refactor Capital, Breakout Ventures, Jeff Dean (SVP of Google AI), Y Combinator, several biotech-focused funds, and senior executives at global pharmaceutical co
Who are the founders of Parallel Biosystems
RD
Robert DiFazio
Co-Founder and CEO
Investors
- Refactor Capital
- Breakout Ventures
- Y Combinator
- Jeff Dean (SVP of Google AI)
- Gaingels
